drugset / Trial / NCT06542237
Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males
NaSequentialOpen-labelOther
Summary
This is a Phase 1b/2a open-label, dose escalation 3 part-study, 28-day, 90-day or 180 day repeat dose study of YCT-529 in healthy males who have decided to have a vasectomy and are waiting for the procedure and for men who have decided not to father children in the future. The study is aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and to assess sexual function and mood.
Timeline
- Start
- 2024-09-11
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YCT-529 | Small molecule | — | Oral |
Indications
No indication recorded.